Search - tctmd.com

Displaying 261 - 280 of 282

Sort: Relevancy | Date

News Industry News

Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

December 16, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

October 12, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

El Punto de Acceso Utilizado para las Cateterizaciones Cardíacas No Influye en la Exposición a la Radiación de los Pacientes

L.A. McKeown

July 27, 2015

News Daily News

Access Site Used for Cardiac Cath Does Not Influence Radiation Exposure for Patients

L.A. McKeown

July 27, 2015

News Industry News

Lilly Provides Update on Evacetrapib Phase 3 Trial

July 27, 2015

News Industry News

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

July 27, 2015

News Industry News

FDA ruling allows heart valve patients to limit blood-thinning medication

July 08, 2015

News Daily News

For CKD Patients, CABG Favored Long-term Over PCIEn Pacientes con ERC, la CABG fue Más Favorable a Largo Plazo que la PCI

Yael L. Maxwell

January 28, 2015

News Daily News

For CKD Patients, CABG Favored Long-term Over PCI

Yael L. Maxwell

January 28, 2015

Presentation TCT 2014

Case #4: Severely Calcified Vessel with Multiple Comorbidities

Presenter: Ajay J. Kirtane, Ramesh Gadepalli

September 13, 2014

Presentation TCT 2014

Case #3: Cardiac Arrest Prior to PCI

Presenter: Ajay J. Kirtane, Ranjit Kumar Nath

September 13, 2014

Presentation TCT 2014

Case #1: Primary PCI of Left Main in Cardiogenic Shock

Presenter: Ajay J. Kirtane, Subroto Mandal

September 13, 2014

News Daily News

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

Caitlin E. Cox

June 24, 2014

News Daily News

CABG Mejor que PCI en Pacientes a Diálisis con Enfermedad Coronaria Compleja

Caitlin E. Cox

June 24, 2014

Presentation TCTAP 2012

Indian TUXEDO Trial In Medically Treated Diabetics

Presenter: Upendra Kaul

April 26, 2012

Advertisement

Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

El Punto de Acceso Utilizado para las Cateterizaciones Cardíacas No Influye en la Exposición a la Radiación de los Pacientes

Access Site Used for Cardiac Cath Does Not Influence Radiation Exposure for Patients

Lilly Provides Update on Evacetrapib Phase 3 Trial

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

FDA ruling allows heart valve patients to limit blood-thinning medication

For CKD Patients, CABG Favored Long-term Over PCIEn Pacientes con ERC, la CABG fue Más Favorable a Largo Plazo que la PCI

For CKD Patients, CABG Favored Long-term Over PCI

Case #4: Severely Calcified Vessel with Multiple Comorbidities

Case #3: Cardiac Arrest Prior to PCI

Case #1: Primary PCI of Left Main in Cardiogenic Shock

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

CABG Mejor que PCI en Pacientes a Diálisis con Enfermedad Coronaria Compleja

Indian TUXEDO Trial In Medically Treated Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content